Volixibat
Modify Date: 2024-01-09 08:19:52
Volixibat structure
|
Common Name | Volixibat | ||
|---|---|---|---|---|
| CAS Number | 1025216-57-2 | Molecular Weight | 805.954 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C38H51N3O12S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of VolixibatVolixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH)[1][2]. |
| Name | volixibat |
|---|---|
| Synonym | More Synonyms |
| Description | Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH)[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Volixibat (SHP626) (5-30 mg/kg; food intake; daily for 24 weeks) improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice[1]. Animal Model: Male Ldlr-/-.Leiden mice (high-fat diet, HFD)[1] Dosage: 5, 15, or 30 mg/kg Administration: Food intake; daily for 24 weeks Result: Significantly increased the total amount of bile acid in feces. Significantly attenuated the HFD-induced increase in hepatocyte hypertrophy, hepatic triglyceride and cholesteryl ester levels, and mesenteric white adipose tissue deposition at the highest dose. Non-alcoholic fatty liver disease activity score (NAS) was significantly lower in volixibat-treated mice than in the HFD controls. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C38H51N3O12S2 |
| Molecular Weight | 805.954 |
| Exact Mass | 805.291443 |
| LogP | 5.35 |
| Index of Refraction | 1.651 |
| X2JZ0451H8 |
| volixibat |
| 3-O-Benzyl-N-({3-[(3S,4R,5R)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydro-1-benzothiepin-5-yl]phenyl}carbamoyl)-6-O-sulfo-β-D-glucopyranosylamine |
| UNII:X2JZ0451H8 |
| β-D-Glucopyranosylamine, N-[[[3-[(3S,4R,5R)-3-butyl-7-(dimethylamino)-3-ethyl-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenyl]amino]carbonyl]-3-O-(phenylmethyl)-, 6-(hydrogen su lfate) |